Back to search
FDAFDA · Food and drugs·Recall number D-1052-2014

Sermorelin/GHRP-6, 3 mg/3 mg, 5 mL vial, Stock # 21740, Compounded by NuVision Pharmacy, Dallas, TX 75244

Published February 5, 2014 · Recall initiated: April 15, 2013

Summary

FDA records drug Class I recall D-1052-2014, published February 5, 2014 and initiated April 15, 2013. Recalling firm: NuVision Pharmacy, Inc.; Status: Terminated; Reported quantity: 122 vials; Lot: Lot #:N10172012@11, Exp 10/17/2013. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: The recall is being initiated due to a lack of sterility assurance and concerns associated with the quality control processes identified during an FDA inspection.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
NuVision Pharmacy, Inc.
Distributor
Nationwide
Lot
Lot #:N10172012@11, Exp 10/17/2013
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Sermorelin/GHRP-6, 3 mg/3 mg, 5 mL vial, Stock # 21740, Compounded by NuVision Pharmacy, Dallas, TX 75244 recalled?

Yes. FDA published recall D-1052-2014 on February 5, 2014. Reported hazard: Lack of Assurance of Sterility: The recall is being initiated due to a lack of sterility assurance and concerns associated with the quality control processes identified during an FDA inspection.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release